Year: 2016
Type: review
Abstract: There is increasing evidence for the involvement of mitochondrial dysfunction and oxidative stress in the pathogenesis of many of the major neurodegenerative and neuroinflammatory diseases, suggesting that mitochondrial and antioxidant pathways may represent potential novel therapeutic targets. Recent years have seen a rapidly growing interest in the use of therapeutic strategies that can limit the defects in, or even to restore, mitochondrial function while reducing free radical generation. The peroxisome proliferation-activated receptor gamma (PPARγ), a ligand-activated transcription factor, has a wide spectrum of biological functions, regulating mitochondrial function, mitochondrial turnover, energy metabolism, antioxidant defence and redox balance, immune responses and fatty acid oxidation. In this review, we explore the evidence for potential beneficial effects of PPARγ agonists in a number of neurological disorders, including Parkinson's disease, Alzheimer's disease, Amyotrophic lateral sclerosis and Huntington's disease, ischaemia, autoimmune encephalomyelitis and neuropathic pain. We discuss the mechanisms underlying those beneficial effects in particular in relation to mitochondrial function, antioxidant defence, cell death and inflammation, and suggest that the PPARγ agonists show significant promise as therapeutic agents in otherwise intractable neurological disease.
Authors: Juan Carlos Corona, Michael R. Duchen
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Keywords: PPARγ, PPARγ agonists, mitochondrial dysfunction, oxidative stress, neurodegenerative diseases, neuroinflammation, Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, ischemia, autoimmune encephalomyelitis, neuropathic pain, antioxidant defense, redox homeostasis, cell death, inflammation, energy metabolism
Open Access status: hybrid
Estimated APC paid: $2,529
Funders: Parkinson's UK, Medical Research Council
OpenAlex ID: W2465564629
